Christiana (Chris) Bardon

MBA ‘03, Harvard University; MD ‘98, Harvard University; SB/SM, Massachusetts Institute of Technology
Chris leads MPM Capital’s public market investing as portfolio manager for BioImpact Equities (formerly known as Burrage Capital) and the Oncology Impact Funds. Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.
Chris leads MPM Capital’s public market investing as portfolio manager for BioImpact Equities (formerly known as Burrage Capital) and the Oncology Impact Funds. Previously, Chris was a health care analyst at Fidelity Investments covering biotechnology, life-science tools and diagnostics, and she started her career as an analyst at MPM. She currently serves on the Harvard Medical School Board of Fellows and is a Trustee of the American Association for Cancer Research Foundation.

Marc Casper

MBA ‘95, Harvard University; BA, Economics, Wesleyan University
Marc was named President and Chief Executive Officer of Thermo Fisher Scientific in 2009 after serving in multiple senior roles at the company. He became Chairman in 2020. Prior to joining Thermo Fisher, Marc served as President, Chief Executive Officer and a director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., where he served as President – Americas. Marc began his career as a strategy consultant at Bain & Company and later joined Bain Capital. He serves on the boards Wesleyan University, Mass General Brigham, and the U.S.-China Business Council.
Marc was named President and Chief Executive Officer of Thermo Fisher Scientific in 2009 after serving in multiple senior roles at the company. He became Chairman in 2020. Prior to joining Thermo Fisher, Marc served as President, Chief Executive Officer and a director of Kendro Laboratory Products. Previously, he worked for clinical diagnostics provider Dade Behring Inc., where he served as President – Americas. Marc began his career as a strategy consultant at Bain & Company and later joined Bain Capital. He serves on the boards Wesleyan University, Mass General Brigham, and the U.S.-China Business Council.

Hannah Chang

MD ‘10, Harvard University; PhD ‘08, Harvard University; BA, Chemistry, Princeton University
Hannah Chang is a Managing Director at Wu Capital, a global evergreen fund. Dr. Chang focuses on early-stage biopharmaceutical venture capital investments out of the firm’s San Francisco office. Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma.

She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice.

Dr. Chang trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.
Hannah Chang is a Managing Director at Wu Capital, a global evergreen fund. Dr. Chang focuses on early-stage biopharmaceutical venture capital investments out of the firm’s San Francisco office. Representative investments include Semma Therapeutics (acquired by Vertex Pharmaceuticals), Korro Bio, Akouos (NASDAQ: AKUS), Gemini Therapeutics (NASDAQ: GMTX), Inipharm, and PACT Pharma.

She was previously an investment professional at 5AM Ventures where she helped found IDEAYA Biosciences (NASDAQ: IDYA) and served as a Board Observer for Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice.

Dr. Chang trained clinically in internal medicine and ophthalmology at the Beth Israel Deaconess Medical Center and Massachusetts Eye and Ear Infirmary, respectively. She is a licensed physician in the District of Columbia.

Andrew Dervan

MBA ’09, Harvard University; MD ’11, Harvard University; BA, Biology, Yale University
Dr. Andrew Dervan is Co-Founder & Chief Operating Officer at Cajal Neuroscience. Prior to Cajal, Andrew was a senior director of business development at Celgene (acquired by Bristol Myers Squibb in 2019). Andrew was responsible for a broad range of business development activities from search and evaluation through definitive document negotiation. He led several completed transactions in the areas of oncology and cell therapy. Andrew held previous roles in translational medicine at Celgene focused on leveraging novel single cell sequencing techniques for target discovery in oncology. Throughout his industry career, Andrew has continued to practice as a clinical geneticist at the University of Washington Medical Center.
Dr. Andrew Dervan is Co-Founder & Chief Operating Officer at Cajal Neuroscience. Prior to Cajal, Andrew was a senior director of business development at Celgene (acquired by Bristol Myers Squibb in 2019). Andrew was responsible for a broad range of business development activities from search and evaluation through definitive document negotiation. He led several completed transactions in the areas of oncology and cell therapy. Andrew held previous roles in translational medicine at Celgene focused on leveraging novel single cell sequencing techniques for target discovery in oncology. Throughout his industry career, Andrew has continued to practice as a clinical geneticist at the University of Washington Medical Center.

Adam Friedman

MD ‘09, Harvard University; PhD ‘09, Harvard University; AB, Molecular Biology, Princeton University
Adam is a physician-scientist and life sciences entrepreneur currently serving as Interim CEO of Scorpion Therapeutics. Previously an Entrepreneur-in-Residence at Atlas Venture, he helped to launch biotechnology companies exploring new areas of biology to alleviate human disease. He has been integral to the launching and building of several Atlas portfolio companies, including co-founding Raze Therapeutics, a next-generation cancer metabolism company. A licensed Massachusetts physician, Dr. Friedman received training in pediatrics at Boston Children’s Hospital. He has authored multiple peer-reviewed publications in the fields of systems biology, cell signaling, genetics, and cancer biology.
Adam is a physician-scientist and life sciences entrepreneur currently serving as Interim CEO of Scorpion Therapeutics. Previously an Entrepreneur-in-Residence at Atlas Venture, he helped to launch biotechnology companies exploring new areas of biology to alleviate human disease. He has been integral to the launching and building of several Atlas portfolio companies, including co-founding Raze Therapeutics, a next-generation cancer metabolism company. A licensed Massachusetts physician, Dr. Friedman received training in pediatrics at Boston Children’s Hospital. He has authored multiple peer-reviewed publications in the fields of systems biology, cell signaling, genetics, and cancer biology.

Steven Hochberg

MBA ’89, Harvard University; BS, Business Administration, University of Michigan
Steve is a Partner at Deerfield Management Company. He has been a founder and manager of healthcare companies for more than twenty-five years. Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies. Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is now the Senior Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $6 billion in annual revenues. Steve is also a Board member of the Cardiovascular Research Foundation.
Steve is a Partner at Deerfield Management Company. He has been a founder and manager of healthcare companies for more than twenty-five years. Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies. Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is now the Senior Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $6 billion in annual revenues. Steve is also a Board member of the Cardiovascular Research Foundation.

Allie Hyans

MBA '20, Harvard University; BSE, Biomedical Engineering, Duke University
Allie began her career at Celgene as an intern while she was an undergraduate biomedical engineering student. Though she started out in the lab, she soon realized that she was more interested in working on the strategy side of the company and moved to a role managing Celgene’s collaborations with biotechnology partners. After business school, Allie continued her career in business development at Regeneron Pharmaceuticals.
Allie began her career at Celgene as an intern while she was an undergraduate biomedical engineering student. Though she started out in the lab, she soon realized that she was more interested in working on the strategy side of the company and moved to a role managing Celgene’s collaborations with biotechnology partners. After business school, Allie continued her career in business development at Regeneron Pharmaceuticals.

Sekar Kathiresan

MD ’97, Harvard University; BA, History, University of Pennsylvania
Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Verve is pioneering a new approach to the care of cardiovascular disease by developing single-course gene-editing therapies that safely and durably lower plasma LDL cholesterol in order to treat cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital Center for Genomic Medicine as well as the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. For his contributions to understanding the inherited basis for cardiovascular disease, Dr. Kathiresan has been honored with a Distinguished Scientist Award from the American Heart Association.
Sekar Kathiresan is co-founder and chief executive officer of Verve Therapeutics. He is also a member of the company’s board of directors. Verve is pioneering a new approach to the care of cardiovascular disease by developing single-course gene-editing therapies that safely and durably lower plasma LDL cholesterol in order to treat cardiovascular disease. Prior to joining Verve, he served as director of the Massachusetts General Hospital Center for Genomic Medicine as well as the Cardiovascular Disease Initiative at the Broad Institute and was professor of medicine at Harvard Medical School. For his contributions to understanding the inherited basis for cardiovascular disease, Dr. Kathiresan has been honored with a Distinguished Scientist Award from the American Heart Association.

Reshma Kewalramani

GMP ‘15, Harvard University; BS/MD ‘98, Boston University
Reshma is the Chief Executive Officer and President at Vertex Pharmaceuticals. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. Prior to Vertex, Reshma spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic. She is also a member of Boston University School of Medicine Dean’s Advisory Board.
Reshma is the Chief Executive Officer and President at Vertex Pharmaceuticals. She joined Vertex in 2017 and was previously the Chief Medical Officer and Executive Vice President of Global Medicines Development and Medical Affairs. Prior to Vertex, Reshma spent more than 12 years at Amgen where she held a variety of roles across Research and Development, including as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and Vice President, U.S. Medical Organization, a group she established and grew to assume responsibility for the full portfolio of molecules. She is a member of the board of directors of the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM, and RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic. She is also a member of Boston University School of Medicine Dean’s Advisory Board.

Benjamine Liu

DPhil ‘16, University of Oxford; MPhil ‘13, University of Cambridge; BS, Biology, Yale University
Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company reimagining drug development.

Benjamine received his DPhil at Oxford as a Rhodes Scholar, conducting his work with Sir Simon Lovestone. His doctoral thesis leveraged machine-learning, AI, and healthcare big-data -- genomics, proteomics, transcriptomics, metabolomics, imaging -- to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease.

During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. TrialSpark is a tech-driven drug development company that can run higher quality clinical trials at a fraction of the time and cost. TrialSpark partners with pharma companies and biotechs to develop drugs through in-licensing clinical stage pharmaceutical assets, NewCo formation, investing equity in companies, and forming unique strategic partnerships to develop therapeutics using our in-house clinical trial engine. Its ultimate mission is to bring new medicines to patients faster, more efficiently, and at lower cost.

Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow.
Benjamine Liu is the co-founder and CEO of TrialSpark, a technology company reimagining drug development.

Benjamine received his DPhil at Oxford as a Rhodes Scholar, conducting his work with Sir Simon Lovestone. His doctoral thesis leveraged machine-learning, AI, and healthcare big-data -- genomics, proteomics, transcriptomics, metabolomics, imaging -- to develop diagnostics and therapeutics for Parkinson’s and Alzheimer’s disease.

During his graduate work, he observed the way clinical trials bottlenecked the development of new treatments for patients, compelling him to start TrialSpark. TrialSpark is a tech-driven drug development company that can run higher quality clinical trials at a fraction of the time and cost. TrialSpark partners with pharma companies and biotechs to develop drugs through in-licensing clinical stage pharmaceutical assets, NewCo formation, investing equity in companies, and forming unique strategic partnerships to develop therapeutics using our in-house clinical trial engine. Its ultimate mission is to bring new medicines to patients faster, more efficiently, and at lower cost.

Before TrialSpark, Ben graduated from Yale where he was awarded the college’s highest honor at graduation and received his MPhil with distinction in Computational Biology from the Department of Applied Mathematics and Theoretical Physics at Cambridge as a Paul Mellon Fellow.

Eileen McCullough

MBA ‘05, Harvard University; BS, Chemistry, Amherst College
Eileen is currently the CEO and co-founder of a biotechnology startup in stealth mode. She most recently served as Senior Vice President of Operations and Corporate Strategy at Vedere Bio prior to its acquisition by Novartis; Vice President of Portfolio Management at Potenza Therapeutics prior to its acquisition; and founding Senior Director, Program Management at Tizona Therapeutics. Eileen has over 20 years of experience in health care entrepreneurship, venture capital, marketing, and finance and has been involved with a number of Biologics, cell therapy and telehealth startups. Over her career, she has helped launch 15 products, in medical devices, therapeutics, and diagnostics. She has also participated in M&A and equity events totaling over $30bn.
Eileen is currently the CEO and co-founder of a biotechnology startup in stealth mode. She most recently served as Senior Vice President of Operations and Corporate Strategy at Vedere Bio prior to its acquisition by Novartis; Vice President of Portfolio Management at Potenza Therapeutics prior to its acquisition; and founding Senior Director, Program Management at Tizona Therapeutics. Eileen has over 20 years of experience in health care entrepreneurship, venture capital, marketing, and finance and has been involved with a number of Biologics, cell therapy and telehealth startups. Over her career, she has helped launch 15 products, in medical devices, therapeutics, and diagnostics. She has also participated in M&A and equity events totaling over $30bn.

Geoffrey Porges

MBA ‘93, Harvard University; MBBS, University of Sydney
Geoff is Senior Managing Director, Director of Therapeutics Research and a Senior Research Analyst at SVB Leerink covering Diversified Biopharmaceutical stocks. He has over 25 years of expertise in advisory, executive and investment roles in the biopharmaceutical industry. Prior to joining SVB Leerink, Geoff established biotechnology research coverage at Sanford C. Bernstein, served as Director of Life Sciences and Chief Operating Officer at BTG PLC and previously served in a variety of positions at Merck & Co, including Head of Worldwide Marketing in the Vaccine Division. Geoff has been consistently ranked as one of Wall Street’s most influential biotechnology analysts.
Geoff is Senior Managing Director, Director of Therapeutics Research and a Senior Research Analyst at SVB Leerink covering Diversified Biopharmaceutical stocks. He has over 25 years of expertise in advisory, executive and investment roles in the biopharmaceutical industry. Prior to joining SVB Leerink, Geoff established biotechnology research coverage at Sanford C. Bernstein, served as Director of Life Sciences and Chief Operating Officer at BTG PLC and previously served in a variety of positions at Merck & Co, including Head of Worldwide Marketing in the Vaccine Division. Geoff has been consistently ranked as one of Wall Street’s most influential biotechnology analysts.

Evan Rachlin

MBA ‘10, Harvard University; MD ‘10, Harvard University; AB, Biochemistry and Japanese, Harvard University
Evan is a Principal at Blackstone Life Sciences. Before joining Blackstone, Evan was the Head of Strategy at Moderna (NASDAQ: MRNA). Before joining Moderna, Evan was a Principal at Bain Capital Ventures and an Engagement Manager at McKinsey & Company in New York.
Evan is a Principal at Blackstone Life Sciences. Before joining Blackstone, Evan was the Head of Strategy at Moderna (NASDAQ: MRNA). Before joining Moderna, Evan was a Principal at Bain Capital Ventures and an Engagement Manager at McKinsey & Company in New York.

Kareem Reda

MBA ’11, Harvard University; BS, Chemical Engineering, Brown University
Kareem is the Chief Business Officer at ElevateBio and Chief Operating Office at LifeEDIT and has more than ten years of experience building partnerships and executing a range of deals in the cell and gene therapy space. Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offering (IPO) and private Series B and C fundraising rounds. At Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). Kareem started his career at Vertex Pharmaceuticals in formulation development.
Kareem is the Chief Business Officer at ElevateBio and Chief Operating Office at LifeEDIT and has more than ten years of experience building partnerships and executing a range of deals in the cell and gene therapy space. Prior to ElevateBio, Kareem was Head of Business Development and Corporate Strategy at Evelo Biosciences. He played an integral role in the company’s $85 million initial public offering (IPO) and private Series B and C fundraising rounds. At Celgene, he executed over a dozen deals with a total value greater than $5 billion and actively partnered with the science team to develop a cancer immunotherapy strategy which ultimately guided Celgene into the rapidly developing field of immuno-oncology (IO). Kareem started his career at Vertex Pharmaceuticals in formulation development.

Mark Robinson

MBA ‘93, Harvard University; BA, History and Political Science, University of California Berkeley
Mark Robinson has over 25 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.

Mark is a Partner at Centerview Partners, one of the largest privately-held independent invesrment banks. Previous to him joining Centerview, Mark was responsible for the global healthcare investment banking practice at Merrill Lynch. During his tenure, Merrill Lynch was the leading equity financier for the biotechnology industry. Additionally, he advised on many notable industry transforming transactions including representing Immunex, the maker of Enbrel, in its $16 billion sale to Amgen, IDEC in its merger with Biogen to create BiogenIdec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa.

Since joining Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical industry most notable representing biotechnology companies on strategic defense. In the period from 2019 to 2021, Centerview represented 18 companies in transactions where the selling price exceeded $1 billion. Immumedics, MyoKardia and Array Biopharma were some of the most prominent clients.

Mark serves on the Board of the College of Letters and Science at U.C. Berkeley and is a member of the Board of Trustees of the U.C. Berkeley Foundation. Under his guidance, the Robinson Program in Life Science Business and Entrepreneurship, a joint undergraduate degree combining Business and Biological Sciences was established at Berkeley in 2018. He is also a Trustee of The Thacher School, as well as a member of the Council on Foreign Relations.
Mark Robinson has over 25 years of investment banking experience, advising many of the most prominent pharmaceutical, biotechnology, and medical device companies in the healthcare industry.

Mark is a Partner at Centerview Partners, one of the largest privately-held independent invesrment banks. Previous to him joining Centerview, Mark was responsible for the global healthcare investment banking practice at Merrill Lynch. During his tenure, Merrill Lynch was the leading equity financier for the biotechnology industry. Additionally, he advised on many notable industry transforming transactions including representing Immunex, the maker of Enbrel, in its $16 billion sale to Amgen, IDEC in its merger with Biogen to create BiogenIdec, Boston Scientific in its $25 billion hostile acquisition of Guidant, Vertex in its acquisition of Aurora and Illumina in its purchase of Solexa.

Since joining Centerview in 2009, the firm has been a leading advisor to the global Biopharmaceutical industry most notable representing biotechnology companies on strategic defense. In the period from 2019 to 2021, Centerview represented 18 companies in transactions where the selling price exceeded $1 billion. Immumedics, MyoKardia and Array Biopharma were some of the most prominent clients.

Mark serves on the Board of the College of Letters and Science at U.C. Berkeley and is a member of the Board of Trustees of the U.C. Berkeley Foundation. Under his guidance, the Robinson Program in Life Science Business and Entrepreneurship, a joint undergraduate degree combining Business and Biological Sciences was established at Berkeley in 2018. He is also a Trustee of The Thacher School, as well as a member of the Council on Foreign Relations.

Howie Rosen

MBA ‘87, Stanford Graduate School of Business; SM, Chemical Engineering, Massachusetts Institute of Technology; BS, Chemical Engineering, Stanford University
Howie is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), where he served as CEO from 2015 to 2017, Aria Pharmaceuticals, Inc., Entrega, Inc., Hammerton, Inc., and Kala Pharmaceuticals, Inc. (NASDAQ: KALA) where he served as Chairman from 2014 to 2016. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning.

Prior to joining Gilead, Howie was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R& D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co.

Mr. Rosen is a Lecturer in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), where he is a Councilor and a Trustee of the NAE Foundation, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents.
Howie is an independent consultant and serves on the board of directors of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), where he served as CEO from 2015 to 2017, Aria Pharmaceuticals, Inc., Entrega, Inc., Hammerton, Inc., and Kala Pharmaceuticals, Inc. (NASDAQ: KALA) where he served as Chairman from 2014 to 2016. From 2004 to 2008, he was Vice President, Commercial Strategy at Gilead Sciences, Inc. where his responsibilities included strategic marketing, global brand management, health economics, competitive intelligence, market research and Gilead’s overall portfolio and business planning.

Prior to joining Gilead, Howie was President of ALZA Corporation where he was responsible for all aspects of managing ALZA as an independent 1000-person operating company within the Johnson & Johnson Family of Companies. Previously at ALZA as Vice President, Product Development, he was responsible for product development activities, portfolio management and corporate and new product planning. Over his 10 years at ALZA, Mr. Rosen also had responsibilities for mergers and acquisitions, R& D planning, and technology ventures. Prior to joining ALZA, Mr. Rosen managed the west coast practice of Integral, Inc., was Director, Corporate Development at GenPharm International, Inc. and was a consultant in the San Francisco office of McKinsey & Co.

Mr. Rosen is a Lecturer in the Department of Chemical Engineering at Stanford and a Lecturer in Management at the Stanford Graduate School of Business. He is also a member of the National Academy of Engineering (NAE), where he is a Councilor and a Trustee of the NAE Foundation, and a Fellow of the American Institute for Medical and Biological Engineering (AIMBE). He is co-inventor on 7 US patents.

Christina Rossi

MBA ’03, Harvard University; BS, Biology, Duke University
Christy is the Chief Commercial Officer of Blueprint Medicines and also serves on the board of directors of Xilio Therapeutics. She has more than 20 years of global pharmaceutical and biotechnology experience. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group.
Christy is the Chief Commercial Officer of Blueprint Medicines and also serves on the board of directors of Xilio Therapeutics. She has more than 20 years of global pharmaceutical and biotechnology experience. Prior to joining Blueprint Medicines, she served as the Multiple Sclerosis (MS) Business Unit Head, North America, at Sanofi Genzyme. In this role, she oversaw all aspects of the financial performance of Sanofi Genzyme’s MS franchise and increased market share for existing products, led the launch of new therapies and optimized operations to accelerate patient access. Previously, Christy served as Vice President, MS Sales, and Vice President, MS Patient and Provider Services, at Sanofi Genzyme. Prior to joining Sanofi Genzyme, she held various roles at Biogen Inc., including Head, Commercial Strategy for Eidetica Biopharma GmbH, Biogen’s biosimilar-focused venture, and U.S. Brand Leader for TYSABRI® (natalizumab). In addition, she consulted in the healthcare practice at the Boston Consulting Group.

Shalini Sharp

MBA ’01, Harvard University; AB, English and American Literature, Harvard University
Shalini has more than 25 years of financial and corporate strategy experience in the life sciences industry. Most recently, she was the Chief Financial Officer (CFO) at Ultragenyx where she was responsible for leading the company's corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was CFO at Agenus Inc., and before that, she worked in corporate strategy at Elan Pharmaceuticals and in management consulting at McKinsey. Shalini serves as a board member of Organon, Mirati Therapeutics, Neurocrine Biosciences, Precision Biosciences, Sutro Biopharma and TB Alliance. She previously served on the boards of Array BioPharma, Panacea Acquisition Corporation and Agenus.
Shalini has more than 25 years of financial and corporate strategy experience in the life sciences industry. Most recently, she was the Chief Financial Officer (CFO) at Ultragenyx where she was responsible for leading the company's corporate finance, strategy, and information technology functions. Prior to Ultragenyx, Ms. Sharp was CFO at Agenus Inc., and before that, she worked in corporate strategy at Elan Pharmaceuticals and in management consulting at McKinsey. Shalini serves as a board member of Organon, Mirati Therapeutics, Neurocrine Biosciences, Precision Biosciences, Sutro Biopharma and TB Alliance. She previously served on the boards of Array BioPharma, Panacea Acquisition Corporation and Agenus.

David Shaywitz

MD ‘99, Harvard University and Massachusetts Institute of Technology (Health Sciences and Technology Program); AB, Biochemistry, Harvard University
David is the founder of Astounding HealthTech Advisory Services and serves a trusted advisor and experienced thought partner to senior R&D leaders as they work through the challenges of effectively leveraging emerging digital and data opportunities in the context of complex pharmaceutical and healthcare organizations. David completed medical training at MGH and conducted postdoctoral research with Doug Melton at the Harvard Stem Cell Institute. He then embarked on a private sector career as Chief Medical Officer at DNAnexus and as a Senior Partner at Takeda Ventures. David has also written extensively about medicine, innovation, technology, and business for a range of popular publications, and since 2015 has co-hosted the popular Tech Tonics podcast.
David is the founder of Astounding HealthTech Advisory Services and serves a trusted advisor and experienced thought partner to senior R&D leaders as they work through the challenges of effectively leveraging emerging digital and data opportunities in the context of complex pharmaceutical and healthcare organizations. David completed medical training at MGH and conducted postdoctoral research with Doug Melton at the Harvard Stem Cell Institute. He then embarked on a private sector career as Chief Medical Officer at DNAnexus and as a Senior Partner at Takeda Ventures. David has also written extensively about medicine, innovation, technology, and business for a range of popular publications, and since 2015 has co-hosted the popular Tech Tonics podcast.

Jim Tananbaum

MBA ‘91, Harvard Business School; MD, Harvard-MIT Health Sciences and Technology Program; BSEE, Electrical Engineering and Computer Science, Yale University; BS, Applied Math, Yale University
Jim is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has approximately $4 billion in assets under management. During the last three decades Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim’s first success came while he was still at HBS, when he co-founded GelTex Pharmaceuticals and brought two drugs to market. Jim was the founding chief executive of Theravance, Inc. His investment experience includes being a co-founder of Prospect Ventures and, earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice.
Jim is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm founded in 2011 that has approximately $4 billion in assets under management. During the last three decades Jim has been a thought partner for some of the most impactful and fastest growth companies of their generation including: 10x Genomics (Nasdaq: TXG), Amerigroup (Nasdaq: ANTM), and Jazz Pharmaceuticals (Nasdaq: JAZZ). Jim’s first success came while he was still at HBS, when he co-founded GelTex Pharmaceuticals and brought two drugs to market. Jim was the founding chief executive of Theravance, Inc. His investment experience includes being a co-founder of Prospect Ventures and, earlier in his career, a partner of Sierra Ventures, where he established its healthcare services investment practice.